CLASS ACTION REMINDER: Berger Montague Advises Innoviz Technologies Ltd. (NASDAQ: INVZ) Investors To Inquire About A Securities Fraud Lawsuit By May 14, 2024


(MENAFN- GlobeNewsWire - Nasdaq) PHILADELPHIA, April 04, 2024 (GLOBE NEWSWIRE) -- Attention Innoviz Technologies Ltd. (“Innoviz” or the“Company”) (NASDAQ: INVZ) Investors. A securities fraud class action lawsuit has been filed against Innoviz on behalf of purchasers of Innoviz's securities between April 21, 2021 and February 28, 2023, inclusive (the“Class Period”) .

CLICK HERE to learn more about the lawsuit.

Important deadline: Investors who purchased or acquired Innoviz securities during the Class Period may, no later than May 14, 2024, seek to be appointed as a lead plaintiff representative of the class.

Innoviz designs and manufactures solid-state light detection and ranging, or“LiDAR,” sensors and develops perception software that purportedly enables the mass production of autonomous vehicles. The Company operates in Europe, Asia Pacific, the Middle East, Africa, and North America.

The truth regarding Innoviz's finances and operations was revealed on March 1, 2023, when Innoviz issued a press release announcing the Company's financial and operational results for its fiscal full-year 2022. Among other items, Innoviz reported GAAP earnings per share of -$0.94, missing consensus estimates by $0.06, and revenue of $6.03 million, missing consensus estimates by $0.96 million. In addition, Innoviz issued guidance for FY 2023 revenue to fall in the range of $12 million to $15 million, significantly below consensus estimates of $30 million.

The Company's disappointing FY 2022 results came as a surprise to investors given that Innoviz had previously extolled the benefits it would derive from its various partnerships with purported“Tier-1 companies.” Indeed, the March 1, 2023 press release said conspicuously little about these supposed collaborations – referencing only its partnerships with BMW and Volkswagen.

On this news, Innoviz's share price fell $0.71 per share, or 14.95%, to close at $4.04 per share on March 1, 2023.

For additional information or to learn how to participate in this litigation, please contact Berger Montague: James Maro at ... or (267) 637-3176, or Andrew Abramowitz at ... or (215) 875-3015 or CLICK HERE .

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

Berger Montague , with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contacts:

James Maro, Senior Counsel
Berger Montague
(267) 637-3176
...

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
...


MENAFN04042024004107003653ID1108059208


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.